bioRxivCancer Biology
Immune-active microenvironment in small cell carcinoma of the ovary, hypercalcemic type: rationale for immune checkpoint blockade
P. Jelinic, J. Ricca, E. Van Oudenhove, N. Olvera, T. Merghoub, D. A. Levine, D. Zamarin
Abstract
Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a highly aggressive monogenic cancer driven by SMARCA4 mutations. Here, we report responses to anti-PD1 immunotherapy in four patients and characterize the immune landscape of SCCOHT tumors using quantitative immunofluorescence and gene expression profiling. Unexpectedly for a low mutation burden cancer, the majority of the tumors demonstrated PD-L1 expression with strong associated T cell infiltration. PD-L1 expression was detected in both tumor and stromal cells, with macrophages being the most abundant PD-L1 positive cells in some tumors. Transcriptional profiling revealed increased expression of genes related to Th1 and cytotoxic cell function in PD-L1 high tumors, suggesting that PD-L1 acts as a pathway of adaptive immune resistance in SCCOHT. These findings suggest that although SCCOHT are low-mutational-burden tumors, their immunogenic microenvironment that resembles the landscape of tumors that respond well to treatment with PD-1/PD-L1 blockade.
- organism: human
- assay: bulk RNA-seq
- assay: imaging
- research focus: host-pathogen & immune response
- research focus: cell type annotation
- research focus: differential expression
- approach: experimental assay
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- γδ T cells modulate anti-tumor immunity in small cell lung cancer
Jin Ng, Yue You, … Kate D. Sutherland·Cancer CellPeer-reviewed·Sep 18, 2026
- Small Cell Lung Cancer Neuroendocrine Subtypes are Associated with Different Immune Microenvironment and Checkpoint Molecule Distribution
D. Dora, C. Rivard, … Z. Lohinai·bioRxiv·Feb 2, 2020
- Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancer
Zhen Zeng, Anastasia Gandini, … Brian G. Gabrielli·British Journal of CancerPeer-reviewed·Apr 7, 2026
- Highly differentiated CD4 T cells Unequivocally Identify Primary Resistance and Risk of Hyperprogression to PD-L1/PD-1 Immune Checkpoint Blockade in Lung Cancer
M. Zuazo-Ibarra, H. Arasanz, … D. Escors·bioRxiv·May 22, 2018
- Landscape of super-enhancers in small cell carcinoma of the ovary, hypercalcemic type and efficacy of targeting with natural product triptolide
J. D. Lang, W. Selleck, … J. M. Trent·iSciencePeer-reviewed·Feb 1, 2025
- Neutralizing PD-L1 and PD-L2 Enhances the Efficacy of Immune Checkpoint Inhibitors in Ovarian Cancer.
Y. R. Miao, K. N. Thakkar, … A. J. Giaccia·bioRxiv·Jan 19, 2020